Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) - Primary endpoint analysis of the CEBIFOX trial

被引：0
|
作者：
Kasper, S. [1 ]
Meiler, J. [1 ]
Knipp, H. [2 ]
Hoehler, T. [3 ]
Reimer, P. [4 ]
Steinmetz, T. [5 ]
Berger, W. [6 ]
Linden, G. [1 ]
Ting, S. [7 ]
Markus, P. [8 ]
Paul, A. [9 ]
Dechene, A. [10 ]
Kostbade, K. [1 ]
Schuler, M. [1 ]
Trarbach, T. [1 ]
机构：
[1] Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol, Essen, Germany
[2] Alfried Krupp von Bohlen & Halbach Hosp, Dept Med 1, Essen, Germany
[3] Prosper Hosp, Dept Med 1, Recklinghausen, Germany
[4] Hosp Essen Werden, Dept Hematol & Med Oncol, Essen, Germany
[5] Grp Practice Hematol Oncol, Cologne, Germany
[6] Catholic Hosp, Dept Hematol & Med Oncol, Essen, Germany
[7] Univ Hosp Essen, West German Canc Ctr, Inst Pathol, Essen, Germany
[8] Elisabeth Hosp, Dept Gen Visceral & Trauma Surg, Essen, Germany
[9] Univ Hosp Essen, West German Canc Ctr, Dept Gen Visceral & Transplantat Surg, Essen, Germany
[10] Univ Hosp Essen, West German Canc Ctr, Dept Gastroenterol & Hepatol, Essen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V328
引用
收藏
页码：99 / 100
页数：2
相关论文
共 50 条
  • [11] PEAK: A randomized phase II study to compare the efficacy of panitumumab plus mFOLFOX6 to bevacizumab plus mFOLFOX6 in patients (pts) with previously untreated, unresectable metastatic colorectal cancer (mCRC) expressing wild-type KRAS
    Schwartzberg, L. S.
    Wagner, V. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [12] Efficacy and safety of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC).
    Zhou, Fuxiang
    Wang Wen-bo
    Xia, Ling
    Dai, Jing
    Wu, Han
    Yang, Lei
    Xiong, Zhiguo
    Gong, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 152 - 152
  • [13] QUALITY OF LIFE ANALYSIS IN PATIENTS WITH KRAS WILD-TYPE METASTATIC COLORECTAL CANCER TREATED WITH FIRST-LINE FOLFIRI PLUS CETUXIMAB
    Lang, I.
    Koehne, C.
    Folprecht, G.
    Rougier, P.
    Curran, D.
    Hitre, E.
    Sartorius, U.
    Griebsch, I.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2012, 23 : 191 - 192
  • [14] PEAK (study 20070509): A randomized phase II study of mFOLFOX6 with either panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) in patients (pts) with unresectable wild-type (WT) KRAS metastatic colorectal cancer (mCRC)
    Steven Schwartzberg, Lee
    Rivera, Fernando
    Karthaus, Meinolf
    Fasola, Gianpiero
    Canon, Jean-Luc
    Yu, Hua
    Go, William Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [15] Efficacy and safety of first-line cetuximab plus FOLFIRI in older and younger patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the CRYSTAL study.
    Van Cutsem, Eric
    Kohne, Claus-Henning
    Folprecht, Gunnar
    Guenther, Silke
    Beier, Frank
    Papamichael, Demetris
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [16] Molecular and clinical predictors of the efficacy of cetuximab in combination with mFOLFOX6 in 1st line treatment of patients (pts) with metastatic colorectal cancer (mCRC) - subgroup analyses of the CEBIFOX trial
    Kasper, S.
    Ting, S.
    Meiler, J.
    Knipp, H.
    Hoehler, T.
    Reimer, P.
    Steinmetz, T.
    Berger, W.
    Linden, G.
    Worm, K.
    Schmid, K. W.
    Markus, P.
    Paul, A.
    Dechene, A.
    Forsting, M.
    Kostbade, K.
    Trarbach, T.
    Schuler, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 100 - 101
  • [17] Prognostic factors in KRAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with biweekly cetuximab (C) plus irinotecan, fluorouracil, and leucovorin (FOLFIRI): A phase II study
    Personeni, Nicola
    Rimassa, Lorenza
    Verusio, Claudio
    Barni, Sandro
    Destro, Annarita
    Raschioni, Carlotta
    Armenia, Silvia
    Floriani, Irene
    Gerardi, Chiara
    Monteforte, Marta
    Villa, Eugenio
    Bozzarelli, Silvia
    Roncalli, Massimo
    Torri, Valter
    Labianca, Roberto
    Santoro, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [18] FOLFOX4 plus cetuximab administered weekly or every two weeks in first-line treatment of patients with KRAS and NRAS wild-type (wt) metastatic colorectal cancer (mCRC)
    Brodowicz, Thomas
    Vrbanec, Damir
    Kaczirek, Klaus
    Ciuleanu, Tudor-Eliade
    Knittelfelder, Regina
    Lindner, Elisabeth
    Messinger, Diethelm
    Zielinski, Christoph
    Streubel, Berthold
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [19] First-line panitumumab versus bevacizumab in combination with mFOLFOX6 for RAS wild-type metastatic colorectal cancer: PARADIGM trial results
    Muro, K.
    Watanabe, J.
    Shitara, K.
    Yamazaki, K.
    Ohori, H.
    Shiozawa, M.
    Yasui, H.
    Oki, E.
    Sato, T.
    Naitoh, T.
    Komatsu, Y.
    Kato, T.
    Hihara, M.
    Soeda, J.
    Yamamoto, K.
    Akagi, K.
    Ochiai, A.
    Uetake, H.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S377 - S377
  • [20] Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC)
    Cervantes, A.
    Macarulla, T.
    Martinelli, E.
    Rodriguez-Braun, E.
    Ciardiello, F.
    Stroh, C.
    Nippgen, J.
    Baselga, J.
    Tabernero, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345